Literature DB >> 8372685

Phenotypic analysis of peripheral T cell lymphoma among the Japanese.

S Nakamura1, T Koshikawa, K Koike, K Kitoh, H Suzuki, A Oyama, T Motoori, M Kojima, M Ogura, S Kurita.   

Abstract

From 1980 to 1990, 174 peripheral T cell lymphomas were studied morphologically and immunophenotypically with a panel of monoclonal antibodies which were reactive with T cell differentiation antigens in cryostat sections and/or cell suspensions. Histologically, 57% of the lymphomas were categorized into low-grade tumors according to the updated Kiel classification, while 41% were high-grade tumors. By immunologic studies, 50% of the lymphomas were of helper/inducer (CD4) phenotype, 6% were of cytotoxic/suppressor (CD8) phenotype, 3% expressed both CD4 and CD8, 3% lacked both CD4 and CD8, and 36% were phenotypically undetermined because of an admixture of a fairly even number of CD4 and CD8-positive cells. The phenotypically undetermined cases were more frequently noted in the low-grade groups than in the high-grade group, and the latter often showed a loss of pan-T antigens, although there was no definite correlation between the histologic category and the immunophenotype. CD25, which is strongly manifested in anti-HTLV-1 antibody-positive cases, was negative or only weakly expressed in anti-HTLV-1 antibody-negative cases. Anaplastic large cell lymphomas (LC-Ana) strongly expressed CD30, which was also detectable in only large blast-like cells in the low-grade tumors. Seventy-one per cent of the lymphomas expressed Ia antigens. In this series, the clinical data were available on 154 patients. For individual markers, the expression of CD30 and HLA-DR were associated with a longer actuarial survival (P < 0.01 and P < 0.05 by the generalized Wilcoxon test). The absence of CD25 or the presence of CD3 on tumor cells correlated with a relatively favorable prognosis, but not significantly. The detection of CD4 and CD8 had relatively little prognostic value. In the cases excluding LC-Ana, a significant difference was also recognized between the groups with and without CD25, CD30 and HLA-DR (P < 0.05 by the generalized Wilcoxon test). These results suggest that the immunophenotypic analysis of peripheral T cell lymphoma provided its use as an adjunct to a histopathologic diagnosis and was related to prognostic prediction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372685     DOI: 10.1111/j.1440-1827.1993.tb01151.x

Source DB:  PubMed          Journal:  Acta Pathol Jpn        ISSN: 0001-6632


  9 in total

1.  Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells.

Authors:  Eva Geissinger; Tobias Odenwald; Seung-Sook Lee; Irina Bonzheim; Sabine Roth; Peter Reimer; Martin Wilhelm; Hans Konrad Müller-Hermelink; Thomas Rüdiger
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

Review 2.  Peripheral T cell lymphoma in Asia.

Authors:  Sanghui Park; Young Hyeh Ko
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

3.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Authors:  Tammy Linlin Song; Maarja-Liisa Nairismägi; Yurike Laurensia; Jing-Quan Lim; Jing Tan; Zhi-Mei Li; Wan-Lu Pang; Atish Kizhakeyil; Giovani-Claresta Wijaya; Da-Chuan Huang; Sanjanaa Nagarajan; Burton Kuan-Hui Chia; Daryl Cheah; Yan-Hui Liu; Fen Zhang; Hui-Lan Rao; Tiffany Tang; Esther Kam-Yin Wong; Jin-Xin Bei; Jabed Iqbal; Nicholas-Francis Grigoropoulos; Siok-Bian Ng; Wee-Joo Chng; Bin-Tean Teh; Soo-Yong Tan; Navin Kumar Verma; Hao Fan; Soon-Thye Lim; Choon-Kiat Ong
Journal:  Blood       Date:  2018-07-27       Impact factor: 22.113

4.  Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies.

Authors:  Eva Geissinger; Irina Bonzheim; László Krenács; Sabine Roth; Philipp Ströbel; German Ott; Peter Reimer; Martin Wilhelm; Hans Konrad Müller-Hermelink; Thomas Rüdiger
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

Review 5.  Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.

Authors:  Kensei Tobinai; Takeshi Takahashi; Shiro Akinaga
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

6.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.

Authors:  Bertrand Coiffier; Barbara Pro; H Miles Prince; Francine Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Franck Morschhauser; Martin Wilhelm; Lauren Pinter-Brown; Swaminathan Padmanabhan Iyer; Andrei Shustov; Tina Nielsen; Jean Nichols; Julie Wolfson; Barbara Balser; Steven Horwitz
Journal:  J Hematol Oncol       Date:  2014-01-23       Impact factor: 17.388

7.  Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma.

Authors:  Annabelle L Rodd; Katherine Ververis; Tom C Karagiannis
Journal:  Clin Med Insights Oncol       Date:  2012-08-21

8.  T-cell lymphomas in South america and europe.

Authors:  Monica Bellei; Carlos Sergio Chiattone; Stefano Luminari; Emanuela Anna Pesce; Maria Elena Cabrera; Carmino Antonio de Souza; Raul Gabús; Lucia Zoppegno; Lucia Zoppegno; Jorge Milone; Astrid Pavlovsky; Joseph Michael Connors; Francine Mary Foss; Steven Michael Horwitz; Raymond Liang; Silvia Montoto; Stefano Aldo Pileri; Aaron Polliack; Julie Marie Vose; Pier Luigi Zinzani; Emanuele Zucca; Massimo Federico
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 9.  Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Lisa Barbarotta; Kristen Hurley
Journal:  J Adv Pract Oncol       Date:  2015 Jan-Feb
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.